Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Feedback secures funding for Oldham pilot
(Sharecast News) - Feedback has secured £50,000 in funding to initiate a Community Diagnostic Centre (CDC) pathway pilot with the Oldham CDC, it announced on Thursday, managed by the Northern Care Alliance. The AIM-traded firm said the funding, obtained under NHS England's CDC programme, came after successful pilots at the Amersham CDC in Buckinghamshire and a pan-regional pilot across Buckinghamshire, Oxfordshire, and Berkshire ICS, as it announced on 19 December.
Under the new contract, Feedback would provide advisory services to the Oldham CDC until 31 March, focusing on pathways development and deploying its leading symptom-based pathway tool, Bleepa.
On meeting initial milestones, Feedback would assist Oldham CDC in seeking additional funding from the 2024-2025 NHS budget to expand the pilot.
The aim was to integrate Bleepa and establish a live breathlessness pathway for patients, drawing insights from ongoing pilots at Amersham CDC and BOB ICS.
That expansion followed the success of the ongoing breathlessness pathway pilot at Queen Victoria Hospital (QVH) and the Sussex Integrated Care System (Sussex ICS).
"We are gaining momentum in the CDC space following the funding support released by NHSE," said chief executive officer Dr Tom Oakley.
"Each additional site builds the evidence base for wider rollout and helps convince the wider NHS of the unquestionable benefits of the symptom-based, straight-to-diagnostic pathway approach.
"A national conversation is growing around how CDCs can be used to drive down waitlists and demonstrates how the NHS can achieve a return on their capital investments to date in building CDCs."
Dr Oakley said that was about leveraging the diagnostic outputs of the CDC to drive down waitlists by integrating them into patient pathways.
"We are focussed on further demonstrating the impact of a pathway approach on CDC utilisation and wider patient wait times - by providing multiple service lines and mutual aid delivery models for sharing workforce capacity at a regional basis through the Bleepa platform.
"We continue to have a number of discussions at the local, regional and national levels with NHS bodies and anticipate further updates in the coming months.
"Furthermore, we are encouraged by the increased NHS spending announced in the Spring Budget, highlighting the importance of investing in digital capabilities for the UK healthcare system."
At 1325 GMT, shares in Feedback were down 4.16% at 115.01p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.